DOCSLIB.ORG

CAS Number Index

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text

Load more

2334 CAS Number Index CAS # Page Name CAS # Page Name CAS # Page Name 50-00-0 905 Formaldehyde 56-81-5 967 Glycerol 61-90-5 1135 Leucine 50-02-2 596 Dexamethasone 56-85-9 963 Glutamine 62-44-2 1640 Phenacetin 50-06-6 1654 Phenobarbital 57-00-1 514 Creatine 62-46-4 1166 α-Lipoic acid 50-11-3 1288 Metharbital 57-22-7 2229 Vincristine 62-53-3 131 Aniline 50-12-4 1245 Mephenytoin 57-24-9 1950 Strychnine 62-73-7 626 Dichlorvos 50-23-7 1017 Hydrocortisone 57-27-2 1428 Morphine 63-05-8 127 Androstenedione 50-24-8 1739 Prednisolone 57-41-0 1672 Phenytoin 63-25-2 335 Carbaryl 50-29-3 569 DDT 57-42-1 1239 Meperidine 63-75-2 142 Arecoline 50-33-9 1666 Phenylbutazone 57-43-2 108 Amobarbital 64-04-0 1648 Phenethylamine 50-34-0 1770 Propantheline bromide 57-44-3 191 Barbital 64-13-1 1308 p-Methoxyamphetamine 50-35-1 2054 Thalidomide 57-47-6 1683 Physostigmine 64-17-5 784 Ethanol 50-36-2 497 Cocaine 57-53-4 1249 Meprobamate 64-18-6 909 Formic acid 50-37-3 1197 Lysergic acid diethylamide 57-55-6 1782 Propylene glycol 64-77-7 2104 Tolbutamide 50-44-2 1253 6-Mercaptopurine 57-66-9 1751 Probenecid 64-86-8 506 Colchicine 50-47-5 589 Desipramine 57-74-9 398 Chlordane 65-23-6 1802 Pyridoxine 50-48-6 103 Amitriptyline 57-92-1 1947 Streptomycin 65-29-2 931 Gallamine 50-49-7 1053 Imipramine 57-94-3 2179 Tubocurarine chloride 65-45-2 1888 Salicylamide 50-52-2 2071 Thioridazine 57-96-5 1966 Sulfinpyrazone 65-49-6 98 p-Aminosalicylic acid 50-53-3 426 Chlorpromazine 58-00-4 138 Apomorphine 66-76-2 632 Dicumarol 50-55-5 1841 Reserpine 58-05-9 1136 Leucovorin 66-79-5 1555 Oxacillin 50-56-6 1582 Oxytocin 58-08-2 315 Caffeine 67-20-9 1505 Nitrofurantoin 50-60-2 1665 Phentolamine 58-14-0 1805 Pyrimethamine 67-56-1 1284 Methanol 50-76-0 39 Actinomycin D 58-15-1 95 Aminopyrine 67-63-0 1086 Isopropanol 50-78-2 27 Acetylsalicylic acid 58-18-4 1373 Methyltestosterone 67-64-1 19 Acetone 50-81-7 2240 Vitamin C 58-22-0 2030 Testosterone 67-66-3 412 Chloroform 51-03-6 1702 Piperonyl butoxide 58-25-3 401 Chlordiazepoxide 67-68-5 674 Dimethylsulfoxide 51-06-9 1752 Procainamide 58-32-2 688 Dipyridamole 68-12-2 670 Dimethylformamide 51-15-0 1730 Pralidoxime 58-38-9 1757 Prochlorperazine 68-19-9 2239 Vitamin B12 51-21-8 882 5-Fluorouracil 58-39-9 1639 Perphenazine 68-26-8 2237 Vitamin A 51-28-5 677 2,4-Dinitrophenol 58-40-2 1763 Promazine 68-35-9 1960 Sulfadiazine 51-34-3 1901 Scopolamine 58-46-8 2033 Tetrabenazine 68-41-7 538 Cycloserine 51-43-4 755 Epinephrine 58-54-8 782 Ethacrynic acid 68-88-2 1030 Hydroxyzine 51-45-6 1005 Histamine 58-55-9 2060 Theophylline 69-23-8 888 Fluphenazine 51-48-9 1152 Levothyroxine 58-61-7 44 Adenosine 69-53-4 118 Ampicillin 51-52-5 1786 Propylthiouracil 58-73-1 682 Diphenhydramine 69-72-7 1890 Salicylic acid 51-55-8 171 Atropine 58-74-2 1593 Papaverine 70-00-8 2157 Trifluridine 51-61-6 706 Dopamine 58-89-9 1161 Lindane 70-26-8 1548 Ornithine 51-67-2 2184 Tyramine 58-93-5 1014 Hydrochlorothiazide 70-30-4 999 Hexachlorophene 51-68-3 1221 Meclofenoxate 58-94-6 421 Chlorothiazide 70-51-9 574 Deferoxamine 51-71-8 1647 Phenelzine 59-01-8 1102 Kanamycin 71-36-3 300 n-Butanol 51-75-2 1220 Mechlorethamine 59-05-2 1301 Methotrexate 71-43-2 209 Benzene 52-01-7 1941 Spironolactone 59-30-3 901 Folic acid 71-55-6 2145 Trichloroethane 52-24-4 2073 Thiotepa 59-42-7 1669 Phenylephrine 71-58-9 1225 Medroxyprogesterone 52-53-9 2219 Verapamil 59-43-8 2064 Thiamine 71-62-5 2221 Veratridine 52-67-5 1612 Penicillamine 59-46-1 1754 Procaine 71-63-6 644 Digitoxin 52-68-6 1383 Metrifonate 59-47-2 1243 Mephenesin 72-20-8 745 Endrin 52-86-8 984 Haloperidol 59-63-2 1081 Isocarboxazid 72-43-5 1310 Methoxychlor 53-02-2 1741 Prednisone 59-66-5 18 Acetazolamide 72-44-6 1286 Methaqualone 53-06-5 512 Cortisone 59-67-6 1473 Niacin 72-63-9 1281 Methandrostenolone 53-19-0 1412 Mitotane 59-92-7 1144 Levodopa 72-69-5 1518 Nortriptyline 53-39-4 1559 Oxandrolone 59-99-4 1468 Neostigmine 73-22-3 2178 Tryptophan 53-43-0 577 Dehydroepiandrosterone 60-00-4 802 EDTA 73-31-4 1231 Melatonin 53-86-1 1060 Indomethacin 60-18-4 2185 Tyrosine 73-48-3 201 Bendroflumethiazide 54-04-6 1261 Mescaline 60-23-1 546 Cysteamine 74-55-5 783 Ethambutol 54-05-7 418 Chloroquine 60-29-7 789 Ether 74-61-3 655 DMPS 54-11-5 1481 Nicotine 60-32-2 90 Aminocaproic acid 74-79-3 145 Arginine 54-31-9 921 Furosemide 60-51-5 656 Dimethoate 74-82-8 1283 Methane 54-64-8 2066 Thimerosal 60-54-8 2037 Tetracycline 74-83-9 1323 Methyl bromide 54-85-3 1084 Isoniazid 60-56-0 1295 Methimazole 74-86-2 24 Acetylene 54-96-6 85 Amifampridine 60-57-1 634 Dieldrin 74-87-3 1327 Methyl chloride 55-38-9 847 Fenthion 60-80-0 136 Antipyrine 74-88-4 1355 Methyl iodide 55-56-1 404 Chlorhexidine 60-87-7 1764 Promethazine 74-90-8 523 Cyanide 55-63-0 1506 Nitroglycerin 60-99-1 1303 Methotrimeprazine 74-98-6 1768 Propane 55-98-1 294 Busulfan 61-00-7 11 Acepromazine 75-00-3 800 Ethyl chloride 56-23-5 346 Carbon tetrachloride 61-33-6 1613 Penicillin G 75-01-4 2235 Vinyl chloride 56-25-7 325 Cantharidin 61-50-7 675 Dimethyltryptamine 75-05-9 20 Acetonitrile 56-38-2 1599 Parathion 61-52-9 2292 Dipropyltryptamine 75-07-0 13 Acetaldehyde 56-40-6 968 Glycine 61-68-7 1226 Mefenamic acid 75-09-2 620 Dichloromethane 56-54-2 1821 Quinidine 61-72-3 488 Cloxacillin 75-15-0 342 Carbon disulfide 56-69-9 1028 5-Hydroxytryptophan 61-73-4 1334 Methylene blue 75-21-8 806 Ethylene oxide 56-75-7 396 Chloramphenicol 61-82-5 106 Amitrole 75-52-5 1507 Nitromethane 2335 75-69-4 878 Fluorocarbons 89-57-6 1260 Mesalamine 108-10-1 1356 Methyl isobutyl ketone 76-06-2 415 Chloropicrin 89-78-1 1238 Menthol 108-46-3 1842 Resorcinol 76-22-2 320 Camphor 89-82-7 1615 Pennyroyal 108-67-8 1262 Mesitylene 76-38-0 1315 Methoxyflurane 90-34-6 1748 Primaquine 108-78-1 1230 Melamine 76-41-5 1578 Oxymorphone 90-82-4 1793 Pseudoephedrine 108-88-3 2110 Toluene 76-42-6 1571 Oxycodone 90-84-6 638 Diethylpropion 108-90-7 410 Chlorobenzene 76-43-7 886 Fluoxymesterone 90-89-1 636 Diethylcarbamazine 108-94-1 532 Cyclohexanone 76-44-8 992 Heptachlor 91-20-3 1455 Naphthalene 108-95-2 1656 Phenol 76-57-3 501 Codeine 91-75-8 133 Antazoline 109-86-4 1314 2-Methoxyethanol 76-58-4 808 Ethylmorphine 91-81-6 2170 Tripelennamine 109-99-9 2046 Tetrahydrofuran 76-73-3 1904 Secobarbital 91-84-9 1804 Pyrilamine 110-46-3 122 Amyl nitrite 76-74-4 1623 Pentobarbital 92-13-7 1688 Pilocarpine 110-54-3 1001 Hexane 76-75-5 2069 Thiopental 92-87-5 212 Benzidine 110-80-5 795 2-Ethoxyethanol 76-99-3 1272 Methadone 93-14-1 979 Guaifenesin 110-82-7 531 Cyclohexane 77-02-1 141 Aprobarbital 93-76-5 2149 2,4,5-T 111-46-6 636 Diethylene glycol 77-07-6 1149 Levorphanol 94-07-5 1978 Synephrine 111-76-2 305 2-Butoxyethanol 77-10-1 1644 Phencyclidine 94-09-7 213 Benzocaine 112-24-3 2154 Trientine 77-19-0 633 Dicyclomine 94-20-2 428 Chlorpropamide 113-15-5 768 Ergotamine 77-20-3 71 Alphaprodine 94-24-6 2034 Tetracaine 113-18-8 788 Ethchlorvynol 77-21-4 964 Glutethimide 94-74-6 328 MCPA 113-42-8 1349 Methylergonovine 77-23-6 1627 Pentoxyverine 94-75-7 622 2,4-D 113-45-1 1364 Methylphenidate 77-26-9 298 Butalbital 94-78-0 1643 Phenazopyridine 113-53-1 709 Dosulepin 77-27-0 2065 Thiamylal 95-25-0 436 Chlorzoxazone 113-59-7 430 Chlorprothixene 77-28-1 303 Butethal 95-50-1 616 o-Dichlorobenzene 114-07-8 773 Erythromycin 77-36-1 435 Chlorthalidone 95-63-6 1792 Pseudocumene 114-26-1 1776 Propoxur 77-37-2 1759 Procyclidine 96-18-4 2150 1,2,3-Trichloropropane 114-86-3 1650 Phenformin 77-41-8 1319 Methsuximide 96-64-0 1936 Soman 114-90-9 1523 Obidoxime chloride 77-65-6 348 Carbromal 96-88-8 1247 Mepivacaine 115-29-7 744 Endosulfan 77-67-8 793 Ethosuximide 97-23-4 621 Dichlorophen 115-32-2 631 Dicofol 77-81-6 1987 Tabun 98-01-1 920 Furfural 115-37-7 2058 Thebaine 77-92-9 457 Citric acid 98-55-5 1695 Pine Oil 115-38-8 1 246 Mephobarbital 78-00-2 2039 Tetraethyllead 98-82-8 520 Cumene 116-06-3 57 Aldicarb 78-11-5 1618 Pentaerythritol tetranitrate 98-92-0 1480 Nicotinamide 116-29-0 2039 Tetradifon 78-30-8 2169 Triorthocresyl phosphate 98-95-3 1503 Nitrobenzene 116-38-1 729 Edrophonium 78-44-4 352 Carisoprodol 98-96-4 1798 Pyrazinamide 117-39-5 1815 Quercetin 78-93-3 1351 Methyl ethyl ketone 99-49-0 360 Carvone 117-89-5 2155 Trifluoperazine 79-01-6 2147 Trichloroethylene 99-66-1 2200 Valproic acid 118-08-1 1013 Hydrastine 79-06-1 36 Acrylamide 99-76-3 1361 Methylparaben 118-42-3 1024 Hydroxychloroquine 79-11-8 408 Chloroacetic acid 99-77-8 693 Disulfiram 118-74-1 998 Hexachlorobenzene 79-24-3 1504 Nitroethane 100-33-4 1619 Pentamidine 118-96-7 2168 Trinitrotoluene 79-57-2 1581 Oxytetracycline 100-41-6 798 Ethylbenzene 119-36-8 1371 Methyl salicylate 80-05-7 241 Bisphenol A 100-42-5 1951 Styrene 120-36-5 625 Dichlorprop 80-08-0 562 Dapsone 100-51-6 219 Benzyl alcohol 121-21-1 1800 Pyrethrin 80-12-6 2050 Tetramine 100-88-9 526 Cyclamate 121-75-5 1203 Malathion 80-56-8 2182 Turpentine 100-92-5 1244 Mephentermine 121-82-4 533 Cyclonite 80-77-3 407 Chlormezanone 100-97-0 1292 Methenamine 122-09-8 1662 Phentermine 81-07-2 886 Saccharin 101-14-4 1333 MOCA 122-14-5 837 Fenitrothion 81-81-2 2253 Warfarin 101-31-5 1031 Hyoscyamine 123-63-7 1594 Paraldehyde 81-90-3 1658 Phenolphthalein 101-40-6 1785 Propylhexedrine 123-91-1 678 Dioxane 82-66-6 681 Diphacinone 101-68-8 1347 MDI 124-38-9 341 Carbon dioxide 82-92-8 527 Cyclizine 101-77-9 1335 4,4'-Methylenedianiline 124-94-7 2138 Triamcinolone 83-26-1 1695 Pindone 103-90-2 14 Acetaminophen 125-28-0 649 Dihydrocodeine 83-43-2 1367 Methylprednisolone 104-14-3 1525 Octopamine 125-29-1 1015 Hydrocodone 83-67-0 2059 Theobromine 104-31-4 214 Benzonatate 125-33-7 1749 Primidone 83-74-9 1035 Ibogaine 105-41-9
Recommended publications
  • WADA Technical Letter – TL07 ANDARINE

    WADA Technical Letter – TL07 ANDARINE

    WADA Technical Letter – TL07 Document Number: TL07 Version Number: 3.0 Written by: WADA Science Approved by: WADA Executive Committee Reviewed by: WADA Laboratory Expert Group Date: 21 December 2020 Effective Date: 1 January 2021 ANDARINE - FLUTAMIDE 1.0 Introduction WADA wishes to draw the attention of the Laboratories to the following observations and instructions on the analysis and reporting of SARM S4 (Andarine) Metabolites O-dephenylandarine and O- dephenylandarine glucuronide. The andarine Metabolites O-dephenylandarine and of O-dephenylandarine glucuronide may also be present in a Sample as a Metabolite of the anti-androgen Flutamide (Drogenil®, Eulexin®, Euflex®, Flutamin®, Flugere®), used primarily in the treatment of prostate cancer [1]. Since flutamide is not a Prohibited Substance in sports, the Laboratories shall not report an Adverse Analytical Finding (AAF) for andarine based on the monitoring of O-dephenylandarine [2]. Figure 1. Proposed metabolic pathway of flutamide and andarine (adapted from Perrenoud et al. [1]). 2.0 Analysis and Reporting Requirements Report the result as an AAF for andarine only when the presence of andarine (parent compound), and/or its glucuronic acid conjugate, and/or its deacetylated and/or hydroxylated Metabolites, and/or its bishydroxylated product [2] are confirmed in the Sample (regardless of the presence of flutamide and/or its Metabolite 2-hydroxyflutamide); [Comment: Laboratories shall not report an AAF for andarine based only on the presence of O- dephenylandarine.] 3.0 References [1] Perrenoud L. et al. Risk of false positive results to SARM S4 in case of therapeutic use of antineoplastic/antiandrogen drug containing flutamide: a case study.
  • The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin Lisa Pasierb

    The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin Lisa Pasierb

    Duquesne University Duquesne Scholarship Collection Electronic Theses and Dissertations Fall 2005 The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin Lisa Pasierb Follow this and additional works at: https://dsc.duq.edu/etd Recommended Citation Pasierb, L. (2005). The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin (Doctoral dissertation, Duquesne University). Retrieved from https://dsc.duq.edu/etd/1021 This Immediate Access is brought to you for free and open access by Duquesne Scholarship Collection. It has been accepted for inclusion in Electronic Theses and Dissertations by an authorized administrator of Duquesne Scholarship Collection. For more information, please contact [email protected]. The Role of Histidine-Rich Proteins in the Biomineralization of Hemozoin A Dissertation presented to the Bayer School of Natural and Environmental Sciences of Duquesne University As partial fulfillment of the requirements for the degree of Doctor of Philosophy By Lisa Pasierb August 26, 2005 Dr. David Seybert, thesis director Dr. David W. Wright, advisor In memory of Anna Pasierb April 24, 1924 – May 31, 2005 ii Acknowledgements First and foremost, I would like to express my sincerest gratitude to my advisor, Dr. David W. Wright. His exuberating energy and conviction attracted me to his research group, while his unwavering faith in me taught me more than he could ever know. Secondly, of course, I would like to extend my appreciation to Glenn Spreitzer and James Ziegler, the other two original members of the Wright group, whom initially tried to exert male dominance, but eventually became very faithful friends and colleagues. Finally, to all the other members of the Wright group over the years, thanks for all of your help, suggestions, and camaraderie.
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T

    WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T

    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
  • (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al

    (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas Et Al

    US 20130253 056A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0253056A1 Nemas et al. (43) Pub. Date: Sep. 26, 2013 (54) CONTINUOUS ADMINISTRATION OF (60) Provisional application No. 61/179,511, filed on May LEVODOPA AND/OR DOPA 19, 2009. DECARBOXYLASE INHIBITORS AND COMPOSITIONS FOR SAME Publication Classification (71) Applicant: NEURODERM, LTD., Ness-Ziona (IL) (51) Int. Cl. A63L/216 (2006.01) (72) Inventors: Mara Nemas, Gedera (IL); Oron (52) U.S. Cl. Yacoby-Zeevi, Moshav Bitsaron (IL) CPC .................................... A6 IK3I/216 (2013.01) USPC .......................................................... 514/538 (73) Assignee: Neuroderm, Ltd., Ness-Ziona (IL) (57) ABSTRACT (21) Appl. No.: 13/796,232 Disclosed herein are for example, liquid aqueous composi (22) Filed: Mar 12, 2013 tions that include for example an ester or salt of levodopa, or an ester or salt of carbidopa, and methods for treating neuro Related U.S. Application Data logical or movement diseases or disorders such as restless leg (63) Continuation-in-part of application No. 12/961,534, syndrome, Parkinson's disease, secondary parkinsonism, filed on Dec. 7, 2010, which is a continuation of appli Huntington's disease, Parkinson's like syndrome, PSP. MSA, cation No. 12/836,130, filed on Jul. 14, 2010, now Pat. ALS, Shy-Drager syndrome, dystonia, and conditions result No. 7,863.336, which is a continuation of application ing from brain injury including carbon monoxide or manga No. 12/781,357, filed on May 17, 2010, now Pat. No. nese intoxication, using Substantially continuous administra 8,193,243. tion of levodopa and/or carbidopa or ester and/or salt thereof.
  • Screening of a Composite Library of Clinically Used Drugs and Well

    Screening of a Composite Library of Clinically Used Drugs and Well

    HHS Public Access Author manuscript Author ManuscriptAuthor Manuscript Author Pharmacol Manuscript Author Res. Author Manuscript Author manuscript; available in PMC 2017 November 01. Published in final edited form as: Pharmacol Res. 2016 November ; 113(Pt A): 18–37. doi:10.1016/j.phrs.2016.08.016. Screening of a composite library of clinically used drugs and well-characterized pharmacological compounds for cystathionine β-synthase inhibition identifies benserazide as a drug potentially suitable for repurposing for the experimental therapy of colon cancer Nadiya Druzhynaa, Bartosz Szczesnya, Gabor Olaha, Katalin Módisa,b, Antonia Asimakopoulouc,d, Athanasia Pavlidoue, Petra Szoleczkya, Domokos Geröa, Kazunori Yanagia, Gabor Töröa, Isabel López-Garcíaa, Vassilios Myrianthopoulose, Emmanuel Mikrose, John R. Zatarainb, Celia Chaob, Andreas Papapetropoulosd,e, Mark R. Hellmichb,f, and Csaba Szaboa,f,* aDepartment of Anesthesiology, The University of Texas Medical Branch, Galveston, TX, USA bDepartment of Surgery, The University of Texas Medical Branch, Galveston, TX, USA cLaboratory of Molecular Pharmacology, Department of Pharmacy, University of Patras, Greece dCenter of Clinical, Experimental Surgery & Translational Research, Biomedical Research Foundation of the Academy of Athens, Greece eNational and Kapodistrian University of Athens, School of Pharmacy, Athens, Greece fCBS Therapeutics Inc., Galveston, TX, USA Abstract Cystathionine-β-synthase (CBS) has been recently identified as a drug target for several forms of cancer. Currently no
  • New Developments in Prokinetic Therapy for Gastric Motility Disorders

    New Developments in Prokinetic Therapy for Gastric Motility Disorders

    REVIEW published: 24 August 2021 doi: 10.3389/fphar.2021.711500 New Developments in Prokinetic Therapy for Gastric Motility Disorders Michael Camilleri* and Jessica Atieh Clinical Enteric Neuroscience Translational and Epidemiological Research (CENTER), Division of Gastroenterology and Hepatology, Mayo Clinic, Rochester, MN, United States Prokinetic agents amplify and coordinate the gastrointestinal muscular contractions to facilitate the transit of intra-luminal content. Following the institution of dietary recommendations, prokinetics are the first medications whose goal is to improve gastric emptying and relieve symptoms of gastroparesis. The recommended use of metoclopramide, the only currently approved medication for gastroparesis in the United States, is for a duration of less than 3 months, due to the risk of reversible or irreversible extrapyramidal tremors. Domperidone, a dopamine D2 receptor antagonist, is available for prescription through the FDA’s program for Expanded Access to Investigational Drugs. Macrolides are used off label and are associated with tachyphylaxis and variable duration of efficacy. Aprepitant relieves some symptoms of gastroparesis. There are newer agents in the pipeline targeting diverse gastric (fundic, antral and pyloric) motor functions, including novel serotonergic 5-HT4 agonists, dopaminergic D2/3 antagonists, neurokinin NK1 antagonists, and ghrelin agonist. Novel Edited by: targets with potential to improve gastric motor functions include the pylorus, macrophage/ Jan Tack, inflammatory function, oxidative
  • Drug-Related Deaths in Scotland in 2019

    Drug-Related Deaths in Scotland in 2019

    Drug-related deaths in Scotland in 2019 Published on 15 December 2020 Statistics of drug-related deaths in 2019 and earlier years, broken down by age, sex, selected drugs reported, underlying cause of death and NHS Board and Council areas. Drug-related deaths in Scotland, 2019 Summary Drug-related deaths Drug-related deaths, 1996 to 2019 continue to increase 1,264 The number of drug-related The dashed line shows the 5-year moving average and the shaded area deaths has increased almost shows the likely range of variation every year. In 2019 there around the 5-year moving average. were 1,264, which is the largest number ever recorded and more than 527 double the number recorded a decade ago. 244 1996 2013 2019 Largest increase was in Drug-related death rates by age group, 2000 to 2019 35-54 year olds 15-24 25-34 35-44 45-54 55-64 Most of the increase in drug related death rates* has 0.6 occurred in the 35-44 year old and 45-54 year old age 0.4 groups. 0.2 0.0 * Deaths per 1,000 people 2000 2019 2000 2019 2000 2019 2000 2019 2000 2019 Death rates vary Drug-related death rates by health board, 2015 to 2019 geographically Greater Glasgow & Clyde 0.27 Tayside 0.21 Greater Glasgow & Clyde Ayrshire & Arran 0.20 had the highest rate* at 0.27 Scotland 0.18 per 1,000 population, Lanarkshire 0.18 Forth Valley 0.17 followed by Tayside and Fife 0.16 Ayrshire & Arran with rates Lothian 0.15 of 0.21 and 0.20 per 1,000 Dumfries & Galloway 0.14 Grampian 0.14 population respectively.
  • 18 December 2020 – to Date)

    18 December 2020 – to Date)

    (18 December 2020 – to date) MEDICINES AND RELATED SUBSTANCES ACT 101 OF 1965 (Gazette No. 1171, Notice No. 1002 dated 7 July 1965. Commencement date: 1 April 1966 [Proc. No. 94, Gazette No. 1413] SCHEDULES Government Notice 935 in Government Gazette 31387 dated 5 September 2008. Commencement date: 5 September 2008. As amended by: Government Notice R1230 in Government Gazette 32838 dated 31 December 2009. Commencement date: 31 December 2009. Government Notice R227 in Government Gazette 35149 dated 15 March 2012. Commencement date: 15 March 2012. Government Notice R674 in Government Gazette 36827 dated 13 September 2013. Commencement date: 13 September 2013. Government Notice R690 in Government Gazette 36850 dated 20 September 2013. Commencement date: 20 September 2013. Government Notice R104 in Government Gazette 37318 dated 11 February 2014. Commencement date: 11 February 2014. Government Notice R352 in Government Gazette 37622 dated 8 May 2014. Commencement date: 8 May 2014. Government Notice R234 in Government Gazette 38586 dated 20 March 2015. Commencement date: 20 March 2015. Government Notice 254 in Government Gazette 39815 dated 15 March 2016. Commencement date: 15 March 2016. Government Notice 620 in Government Gazette 40041 dated 3 June 2016. Commencement date: 3 June 2016. Prepared by: Page 2 of 199 Government Notice 748 in Government Gazette 41009 dated 28 July 2017. Commencement date: 28 July 2017. Government Notice 1261 in Government Gazette 41256 dated 17 November 2017. Commencement date: 17 November 2017. Government Notice R1098 in Government Gazette 41971 dated 12 October 2018. Commencement date: 12 October 2018. Government Notice R1262 in Government Gazette 42052 dated 23 November 2018.
  • Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition

    Supplement Ii to the Japanese Pharmacopoeia Fifteenth Edition

    SUPPLEMENT II TO THE JAPANESE PHARMACOPOEIA FIFTEENTH EDITION Official From October 1, 2009 English Version THE MINISTRY OF HEALTH, LABOUR AND WELFARE Notice: This English Version of the Japanese Pharmacopoeia is published for the conven- ience of users unfamiliar with the Japanese language. When and if any discrepancy arises between the Japanese original and its English translation, the former is authentic. The Ministry of Health, Labour and Welfare Ministerial Notification No. 425 Pursuant to Paragraph 1, Article 41 of the Pharmaceutical Affairs Law (Law No. 145, 1960), we hereby revise a part of the Japanese Pharmacopoeia (Ministerial Notification No. 285, 2006) as follows*, and the revised Japanese Pharmacopoeia shall come into ef- fect on October 1, 2009. However, in the case of drugs which are listed in the Japanese Pharmacopoeia (hereinafter referred to as “previous Pharmacopoeia”) [limited to those listed in the Japanese Pharmacopoeia whose standards are changed in accordance with this notification (hereinafter referred to as “new Pharmacopoeia”)] and drugs which have been approved as of October 1, 2009 as prescribed under Paragraph 1, Article 14 of the same law [including drugs the Minister of Health, Labour and Welfare specifies (the Ministry of Health and Welfare Ministerial Notification No. 104, 1994) as those ex- empted from marketing approval pursuant to Paragraph 1, Article 14 of the Pharmaceu- tical Affairs Law (hereinafter referred to as “drugs exempted from approval”)], the Name and Standards established in the previous Pharmacopoeia (limited to part of the Name and Standards for the drugs concerned) may be accepted to conform to the Name and Standards established in the new Pharmacopoeia before and on March 31, 2011.
  • Gait Analysis in Advanced Parkinson's Disease – Effect of Levodopa And

    Gait Analysis in Advanced Parkinson's Disease – Effect of Levodopa And

    ORIGINAL ARTICLE Gait Analysis in Advanced Parkinson’s Disease – Effect of Levodopa and Tolcapone Din-E Shan, Shwn-Jen Lee, Ling-Yi Chao, and Shyh-Ing Yeh ABSTRACT: Objective: To determine the therapeutic effect of levodopa/benserazide and tolcapone on gait in patients with advanced Parkinson’s disease. Methods: Instrumental gait analysis was performed in 38 out of 40 patients with wearing-off phenomenon during a randomized, double-blind, placebo- controlled trial of tolcapone. R e s u l t s : Gait analysis disclosed a significant improvement by levodopa/benserazide in walking speed, stride length and the range of motion of hip, knee and ankle joints. At the end of the study, both the UPDRS motor scores during off-period and the percentage of off time improved significantly using tolcapone. However, gait analysis could not confirm this improvement. With respect to levodopa/benserazide effect, the reduction in rigidity correlated with improved angular excursion of the ankle, whereas the decreased bradykinesia correlated with improved stride length and angular excursion of the hip and knee joints. Conclusion: The results of our gait analysis confirmed that in parkinsonian patients with fluctuating motor symptoms levodopa/benserazide, but not tolcapone, produced a substantial improvement. RÉSUMÉ: Analyse de la démarche chez les patients en phase avancée de la maladie de Parkinson – Effet de la lévodopa et du tolcapone. Objectif: Le but de cette étude était de déterminer l’effet thérapeutique de la lévodopa/bensérazide et du tolcapone sur la démarche, chez les patients en phase avancée de la maladie de Parkinson. Méthodes: Une analyse instrumentale de la démarche a été réalisée chez 38 de 40 patients ayant un phénomène de détérioration de fin de dose pendant un essai randomisé, en double insu, contrôlé par placebo, du tolcapone.
  • Dalbavancin • Oritavancin • Tedizolid • Ceftolozane/Tazobactam • Ceftazidime/Avibactam • Fecal Transplant

    Dalbavancin • Oritavancin • Tedizolid • Ceftolozane/Tazobactam • Ceftazidime/Avibactam • Fecal Transplant

    What’s New in Infectious Diseases? Bruce L. Gilliam, M.D. Institute of Human Virology University of Maryland School of Medicine Baltimore, MD Topics New Antibacterial Therapeutics Emerging Pathogens HIV Hepatitis C Disclosures Research Studies Pfizer – Staph aureus Vaccine Trial TaiMed Biologics - Ibaluzimab Advisory Board Viiv Healthcare New Antibacterial Therapeutics • Dalbavancin • Oritavancin • Tedizolid • Ceftolozane/tazobactam • Ceftazidime/avibactam • Fecal Transplant Incidence of Staph aureus hospitalizations in U.S.A., 2001–2009 BMC Infect Dis 2014, 14:296 Dalbavancin (Dalvance) • Derived from Teicoplanin • ½ life – Effective: 8.5 days – Terminal: 346 hrs (14 days) • Bactericidal • Similar spectrum to Vancomycin, active against: – Staphylococci • MSSA, MRSA, CoNS – Streptococci • resistant pneumococci • anaerobic strep – Enterococci • VRE with van B, C but not A – Corynebacterium Dalbavancin Once Weekly Non- Inferior to Vanco/Linezolid N Engl J Med 2014;370:2169-79. Single-Dose (1.5 g) Non-Inferior to Weekly Dalbavancin for Treatment of Acute Bacterial Skin and Skin Structure Infection 100 90 80 70 60 50 Single Dose 40 Once Weekly 30 20 10 0 Overall Clinical Success Rate Success Rate Success Rate Response Day 14 Day 28 Day 14 MRSA Clin Infect Dis. 2015 Nov 26. pii: civ982. [Epub ahead of print] VA Experience with Dalbavancin • Background – Levels in bone > MIC for 14 days • 8 patients treated for osteomyelitis with IV Dalbavancin – Former IV drug users not eligible for home IV or unwilling to do home IV • Treated for up to 8 weeks • No adverse events • All with resolution of osteomyelitis • Cost savings vs. placement in facility Oritavancin (Orbactiv) • Derived from Vancomycin • ½ life – Terminal 245-393 hrs (10-16 days) • Bactericidal • Similar spectrum to Vancomycin, active against: – Staphylococci • MSSA, MRSA, CoNS – Streptococci • resistant pneumococci • anaerobic strep – Enterococci • VRE with van A, B, C – Corynebacterium Single Dose Oritavancin vs.
  • International Journal of Medicine and Pharmaceutical Research

    International Journal of Medicine and Pharmaceutical Research

    Wayal Sunil Anil et al, IJMPR, 2019, 7(6): 180-183 CODEN (USA): IJCPNH | ISSN: 2321-2624 International Journal of Medicine and Pharmaceutical Research Journal Home Page: www.pharmaresearchlibrary.com/ijmpr R E S E A R C H A R T I C L E Formulation and In-vitro Evaluation of Alosetron Oral Thin Films Wayal Sunil Anil1, G.S. Valluri2, Gampa Vijay Kumar3 Department of Pharmacy, KGR Institute of Technology and Management, Rampally, Kesara, Medchal, Telangana, India. A B S T R A C T Alosetron, is a 5-HT3 antagonist used for the management of severe diarrhea-predominant irritable bowel syndrome. In present study oral thin films of Alosetron were developed to have a faster on set of action. The oralthin films were developed by using polymers Guar gum, Pullulan and PVP K30.Oral thin films were prepared by employing solvent casting method. Propylene glycol was selected as permeation enhancer and plasticizer. Drug excipient compatibility studies were carried out by using FTIR, and it was observed that there were no interactions. Formulations were prepared with the varying concentrations polymers ranging from F1-F9, and all the formulations were evaluated for various physical parameters Physical appearance, Weight variation, Thickness, Folding endurance, Tensile strength, Drug content, Moisture uptake, Moisture content and all the results were found to be were found to be within the pharmacopeial limits, in-vitro drug release studies by using USP dissolution Apparatus Type II. Among all the 9 formulations F4 formulation which contain Pullulan 10mg and shown 97.06% cumulative drug release within 30 min.